• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell completes up to US$25 million in debt financing

by alex | Sep 24, 2026 | Latest News

Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference

by admin | Sep 3, 2026 | Latest News

H.C. Wainwright 28th Annual Global Investment Conference

by admin | Sep 3, 2026 | Investor Presentations

Recent Posts

  • Scancell completes up to US$25 million in debt financing
  • Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference
  • H.C. Wainwright 28th Annual Global Investment Conference
  • Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
  • Strategic transactions to unlock longer-term value

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy